INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Corporate insider
PB

Piekos Brian

Chief Financial OfficerCIK 0001815308

EDGAR filingsOpen in network
Disclosed transactions11
Buys / sells0 / 2
Max Insider Score42
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
21.7K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    KalVista Pharmaceuticals, Inc.Chief Financial Officer · Nov 26, 2025
5
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D
—
55.0K sh
Jun 11, 2026
Jun 11, 2026
traded Jun 11, 2026
+0d
SEC FORM 4

Evidence

5
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
93.8K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

5
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Disposition to issuer
D—
100.0K sh
Jun 11, 2026Jun 11, 2026
traded Jun 11, 2026
+0dSEC FORM 4

Evidence

13
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
6,250 sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

31
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Open-market sale
SELL$38K
1,862 sh
Apr 17, 2026Apr 20, 2026
traded Apr 17, 2026
+3dSEC FORM 4

Evidence

9
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
6,250 sh
Apr 16, 2026Apr 20, 2026
traded Apr 16, 2026
+4dSEC FORM 4

Evidence

11
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Grant or award
A—
100.0K sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC FORM 4

Evidence

23
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
15.0K sh
Nov 21, 2025Nov 26, 2025
traded Nov 21, 2025
+5dSEC FORM 4

Evidence

15
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Option exercise
M—
15.0K sh
Nov 21, 2025Nov 26, 2025
traded Nov 21, 2025
+5dSEC FORM 4

Evidence

42
PB
Piekos BrianChief Financial Officer
KALVKalVista Pharmaceuticals, Inc.
Open-market sale
SELL$60K
4,471 sh
Nov 24, 2025Nov 26, 2025
traded Nov 24, 2025
+2dSEC FORM 4

Evidence